Poolbeg Pharma (POLB) H1 2026 earnings summary

Executive summary

• Advanced POLB 001 through regulatory, operational, and commercial milestones, including MHRA CTA and positive FDA pre-IND meeting.

• Initiated the TOPICAL trial in relapsed/refractory multiple myeloma patients, with eight of ~30 participants dosed and strong recruitment momentum.

• Strengthened intellectual property portfolio with new patent grants in multiple jurisdictions.

• Expanded Scientific Advisory Board with appointment of a cancer immunotherapy expert.

Financial highlights

• Cash balance of £4.8 million as of 30 June 2026, down from £10.0 million at 30 June 2025.

• Loss for the period was £1.9 million, improved from £2.2 million in H1 2025.

• R&D expenses increased to £0.9 million (H1 2025: £0.5 million); administrative expenses decreased to £1.3 million (H1 2025: £2.0 million).

• Successful £3.5 million fundraising in July 2026, extending cash runway into Q2 2028.

Outlook and guidance

• Both POLB 001 TOPICAL and oral GLP-1 proof-of-concept trials are fully funded through completion.

• Oral GLP-1 proof-of-concept study expected to commence in H2 2026.

• Focus remains on continued recruitment for the TOPICAL trial and advancing partnering discussions.